We use analytics to improve your experience. Cookie policy
NYSE · HEALTHCARE · Statistics
Valuation, profitability, balance-sheet health, and risk metrics for TMO — every field resolved through TECHi's unified provider chain (Yahoo → FMP → Finnhub → Alpha Vantage) and labelled with the winning source.
Market cap
$174.37B
Enterprise value
—
P/E (TTM)
25.77
Forward P/E
18.83
PEG ratio
1.54
Lower = cheaper for the growth
Price / sales
—
Price / book
—
EPS (TTM)
$18.21
Valuation read
A trailing P/E in line with the broad market means TMO is being priced like an average earner. The PEG ratio (1.54) is the cleaner read here — it tells you how much you're paying per unit of growth.
Gross margin
—
Operating margin
—
Net margin
15.10%
Return on equity
—
Return on assets
—
Debt / equity
—
Current ratio
—
>1 = covers near-term liabilities
Beta (5Y)
0.97
Profitability read
Margins in the high single-digits to high-teens are the bulk of the index. The differentiated reads here are operating-margin direction (improving = leverage) and ROE — the latter tells you how much equity capital management actually needs.
Dividend yield
0.37%
Forward yield
Shares outstanding
—
52w high
$643.35
52w low
$384.44
Frequently asked
Thermo Fisher Scientific Inc. (TMO) has a market capitalization of $174.4 billion, computed from the latest share count and the live TMO quote price on TECHi.
TMO trades at a trailing P/E of 25.77. Forward P/E and PEG are visible alongside on the Statistics page; compare to the sector cohort on /quote/TMO/peers/.
Each metric on the TMO Statistics page is resolved through TECHi's unified-fundamentals layer — Yahoo, FMP, Finnhub, Alpha Vantage in priority order — and labelled with the winning provider so you can verify any number.
Live quote-derived stats (52-week range, current ratio, beta) refresh every market session; reported fundamentals (margins, ROE, debt-to-equity) update each time the issuer files a new statement.
